|
MRUS
|
Merus N.V.
|
0.09%
|
US
|
NASDAQ
|
|
MDGL
|
Madrigal Pharmaceuticals, Inc.
|
0.09%
|
US
|
NASDAQ
|
|
KYMR
|
Kymera Therapeutics, Inc.
|
0.09%
|
US
|
NASDAQ
|
|
GOSS
|
Gossamer Bio, Inc.
|
0.09%
|
US
|
NASDAQ
|
|
FGEN
|
FibroGen, Inc
|
0.09%
|
US
|
NASDAQ
|
|
ENTA
|
Enanta Pharmaceuticals, Inc.
|
0.09%
|
US
|
NASDAQ
|
|
EDIT
|
Editas Medicine, Inc.
|
0.09%
|
US
|
NASDAQ
|
|
DSGN
|
Design Therapeutics, Inc.
|
0.09%
|
US
|
NASDAQ
|
|
NGM
|
NGM Biopharmaceuticals, Inc.
|
0.09%
|
US
|
NASDAQ
|
|
RETA
|
Reata Pharmaceuticals, Inc. - Class A
|
0.08%
|
US
|
NASDAQ
|
|
REPL
|
Replimune Group, Inc.
|
0.08%
|
US
|
NASDAQ
|
|
RCKT
|
Rocket Pharmaceuticals, Inc.
|
0.08%
|
US
|
NASDAQ
|
|
PACB
|
Pacific Biosciences of California, Inc.
|
0.08%
|
US
|
NASDAQ
|
|
MORF
|
Morphic Holding, Inc.
|
0.08%
|
US
|
NASDAQ
|
|
KURA
|
Kura Oncology, Inc.
|
0.08%
|
US
|
NASDAQ
|
|
INVA
|
Innoviva, Inc.
|
0.08%
|
US
|
NASDAQ
|
|
IMGN
|
ImmunoGen, Inc.
|
0.08%
|
US
|
NASDAQ
|
|
GRFS
|
Grifols, S.A.
|
0.08%
|
US
|
NASDAQ
|
|
CRNX
|
Crinetics Pharmaceuticals, Inc.
|
0.08%
|
US
|
NASDAQ
|
|
ACRS
|
Aclaris Therapeutics, Inc.
|
0.08%
|
US
|
NASDAQ
|